Key Points
- Director Guy Nohra sold 10,000 shares on Dec. 4 at an average price of $7.57 for proceeds of $75,700, trimming his stake by 7.90% to 116,610 shares (valued at about $882,738.70).
- Bioventus stock recently traded near $7.19 with a 1‑year range of $5.81–$11.85, a market cap of about $595.07 million and a negative P/E of -11.79.
- Institutional investors own about 62.94% of the company, with sizable recent additions including Nantahala Capital raising its position to 5.28M shares (a 28% increase).
Bioventus Inc. (NYSE:BVS - Get Free Report) Director Guy Nohra sold 10,000 shares of the stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $7.57, for a total transaction of $75,700.00. Following the transaction, the director owned 116,610 shares in the company, valued at approximately $882,737.70. The trade was a 7.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Bioventus Price Performance
Bioventus stock opened at $7.19 on Tuesday. Bioventus Inc. has a 1 year low of $5.81 and a 1 year high of $11.85. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The firm has a 50 day moving average price of $7.09 and a 200 day moving average price of $6.93. The company has a market cap of $595.07 million, a price-to-earnings ratio of -11.79 and a beta of 0.79.
Institutional Trading of Bioventus
Institutional investors and hedge funds have recently made changes to their positions in the company. Nantahala Capital Management LLC raised its position in shares of Bioventus by 28.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company's stock worth $34,959,000 after buying an additional 1,155,192 shares during the period. Nuveen LLC acquired a new stake in Bioventus during the first quarter worth about $4,700,000. Kent Lake PR LLC purchased a new position in shares of Bioventus in the 2nd quarter worth about $2,317,000. Driehaus Capital Management LLC lifted its stake in shares of Bioventus by 29.1% in the 1st quarter. Driehaus Capital Management LLC now owns 1,445,257 shares of the company's stock valued at $13,224,000 after purchasing an additional 325,402 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its stake in shares of Bioventus by 219.6% in the 3rd quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company's stock valued at $3,088,000 after purchasing an additional 317,157 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.
Bioventus Company Profile
(
Get Free Report)
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
